An overview of the efficacy and signaling pathways activated by stem cell-derived extracellular vesicles in diabetic kidney disease.
Front Endocrinol (Lausanne)
; 13: 962635, 2022.
Article
in En
| MEDLINE
| ID: mdl-35966088
Diabetic kidney disease (DKD) is one of complications of diabetes mellitus with severe microvascular lesion and the most common cause of end-stage chronic kidney disease (ESRD). Controlling serum glucose remains the primary approach to preventing and slowing the progression of DKD. Despite considerable efforts to control diabetes, people with diabetes develop not only DKD but also ESRD. The pathogenesis of DKD is very complex, and current studies indicate that mesenchymal stromal cells (MSCs) regulate complex disease processes by promoting pro-regenerative mechanisms and inhibiting multiple pathogenic pathways. Extracellular vesicles (EVs) are products of MSCs. Current data indicate that MSC-EVs-based interventions not only protect renal cells, including renal tubular epithelial cells, podocytes and mesangial cells, but also improve renal function and reduce damage in diabetic animals. As an increasing number of clinical studies have confirmed, MSC-EVs may be an effective way to treat DKD. This review explores the potential efficacy and signaling pathways of MSC-EVs in the treatment of DKD.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus
/
Diabetic Nephropathies
/
Mesenchymal Stem Cells
/
Extracellular Vesicles
/
Kidney Failure, Chronic
Limits:
Animals
/
Humans
Language:
En
Journal:
Front Endocrinol (Lausanne)
Year:
2022
Document type:
Article
Affiliation country:
China
Country of publication:
Switzerland